STOCK TITAN

vvy - $vvy STOCK NEWS

Welcome to our dedicated page for vvy news (Ticker: $vvy), a resource for investors and traders seeking the latest updates and insights on vvy stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect vvy's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of vvy's position in the market.

Rhea-AI Summary
Vivoryon Therapeutics shares highlights from virtual R&D event with key opinion leaders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Vivoryon Therapeutics N.V. announces Virtual R&D Event with Key Opinion Leaders and upcoming conference participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Vivoryon Therapeutics N.V. appoints new executive directors after shareholders approve all items at the Extraordinary General Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
Vivoryon Therapeutics reports H1 2023 financial results and operational progress. VIVIAD and VIVA-MIND studies on track. Varoglutamstat shows encouraging safety data. Bolstered financial position with successful private placement of EUR 25 million. Final data from VIVIAD expected in Q1/2024. Study update on VIVA-MIND expected in Q4/2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Vivoryon Therapeutics N.V. to report half-year 2023 financial results and operational progress on September 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Vivoryon Therapeutics N.V. (VVY) to Hold Extraordinary General Meeting to Confirm New Executive Director Appointments. The meeting will include the appointment of two new members to the Board of Directors, including the current Chief Medical Officer as the new CEO and the Head of Investor Relations as the Chief Strategy & Investor Relations Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Vivoryon Therapeutics N.V. has announced the appointment of Dr. Frank Weber as Chief Executive Officer. Dr. Weber, the current Chief Medical Officer, will lead the company through the next stage of development with a focus on the upcoming VIVIAD trial readout in 1Q24. The company also announced the appointment of Anne Doering as Chief Strategy & Investor Relations Officer. Vivoryon will report its first half 2023 financial results and operational progress on September 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
-
Rhea-AI Summary
Vivoryon Therapeutics N.V. has announced the outcome of its 2023 Annual General Meeting. All proposed resolutions were approved, and two new Non-Executive Board members, Kugan Sathiyanandarajah and Professor Dr. Morten Asser Karsdal, were elected. The company is focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
vvy

Nasdaq:VVY

VVY Rankings

VVY Stock Data